MARTINELLI, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 970
EU - Europa 189
AS - Asia 74
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.239
Nazione #
US - Stati Uniti d'America 966
SE - Svezia 52
UA - Ucraina 43
IT - Italia 38
CN - Cina 29
IN - India 24
SG - Singapore 21
FI - Finlandia 19
BG - Bulgaria 12
GB - Regno Unito 10
DE - Germania 5
CA - Canada 4
IE - Irlanda 4
RO - Romania 4
TG - Togo 2
AR - Argentina 1
BE - Belgio 1
EU - Europa 1
MU - Mauritius 1
NL - Olanda 1
ZA - Sudafrica 1
Totale 1.239
Città #
Fairfield 172
Woodbridge 142
Houston 85
Ashburn 81
Seattle 74
Cambridge 60
Chandler 60
Wilmington 58
Ann Arbor 44
San Paolo di Civitate 26
Beijing 24
Plano 17
Princeton 17
Millbury 14
Lawrence 13
Jacksonville 12
Sofia 12
Singapore 11
Rome 9
Boardman 6
Boston 4
Dublin 4
San Diego 4
Toronto 4
Dearborn 3
Falls Church 3
Andover 2
Bühl 2
Des Moines 2
Kunming 2
Lomé 2
Norwalk 2
Auburn Hills 1
Bremen 1
Brescia 1
Brussels 1
Federal 1
Jinan 1
London 1
Muizenberg 1
Nanning 1
New York 1
Nuremberg 1
Philadelphia 1
Redmond 1
San Francisco 1
San Mateo 1
Trento 1
Ürümqi 1
Totale 988
Nome #
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes 103
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment 88
NILOTINIB FOR THE FRONTLINE TREATMENT OF PH(+) CHRONIC MYELOID LEUKEMIA. 87
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up 84
Treatment of philadelphia-positive chronic myeloid leukemia with imatinib: Importance of a stable molecular response 84
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML working party. 83
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. 80
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. 77
A comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study 75
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older 72
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) 68
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 60
null 52
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report 48
null 48
null 46
null 46
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients 23
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party 11
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 9
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 8
Totale 1.252
Categoria #
all - tutte 2.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.878


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020336 41 11 2 18 36 34 43 47 40 29 25 10
2020/202183 12 17 5 6 2 6 0 6 12 8 8 1
2021/2022180 1 13 22 6 27 4 4 17 7 19 24 36
2022/2023221 29 55 6 26 27 32 0 9 34 0 2 1
2023/202456 7 16 1 0 2 11 0 1 0 12 4 2
2024/20256 6 0 0 0 0 0 0 0 0 0 0 0
Totale 1.252